Uncrewed warships are simple answers to big US Navy problems, says a defense tech company that's building them
Blue Water Autonomy, a relatively new defense technology company building uncrewed warships, believes that these vessels are the answer to the Navy's troubles and could give the sea service a much-needed boost in future conflicts for a lower cost.
"There is a gap in the US Navy's overall capabilities," Austin Gray, Blue Water's co-founder and chief strategy officer, told Business Insider. "Human crewed ships would never be able to offer a 20 to 30 million dollar platform that can go out on the open ocean and do a bunch of different stuff."
Blue Water, founded in 2024 by former Navy officers and an engineer, announced $14 million in seed funding earlier in April. This Boston-based startup is building a fully autonomous warship that can be mass-produced and operate alongside crewed vessels in the future.
The Navy, which plans to build a battle force of 381 crewed warships and 134 uncrewed surface and undersea vessels, already fields various drone vessels, some designed for surveillance and reconnaissance missions and others as combat platforms.
Gray, a former Navy intelligence officer, said that many of these vessels cannot travel thousands of miles and carry large payloads and are better off protecting key choke points, like the Strait of Hormuz or ports, rather than being sent on endurance missions.
As US military leaders prepare for a potential war against China, they are paying close attention to America's naval force, as a conflict between the two adversaries would likely involve substantial maritime combat. Amid a push to supplement the traditional fleet with drones, the vast openness of the Western Pacific means it's essential for the Navy to have platforms that can travel long distances across the open ocean, a blue-water fleet.
"How do we start something outside Chinese missile range, like 2,000 miles back, go into missile range — operate, conduct a mission — and then get back out?" Gray said. This is where Blue Water hopes to make a splash.
First, the ship must be large enough to hold enough fuel to travel thousands of miles and carry an engine or two, bringing the vessel's length to roughly 100 feet. Gray said a ship this size is better off as autonomous because squeezing things like supportive and defensive systems on a small, crewed vessel "would be a disaster."
"It'd be uncomfortable for the crew," he said, and that doesn't even factor in all the added systems that can make a warship's design more complex. "So, it's just much better to keep a vessel of that size unmanned since the tech is there."
Blue Water believes a fleet of autonomous vessels can effectively solve a major hindrance in the Navy's preparation for a potential war with war: the need to build a larger naval force without adding strain to America's already struggling shipbuilding industry.
China already has a larger naval force than the US, and its shipyards are rapidly building new surface combatants. By contrast, America's shipbuilding industry has deteriorated so much that President Donald Trump signed an executive order earlier this month to revive it.
Adm. Samuel Paparo, the head of US Indo-Pacific Command, told lawmakers recently that China is building around three warships for every one that America makes. He previously said uncrewed systems could help fill the gap for what the Navy lacks in crewed vessels.
Gray said that autonomous vessels could be produced without adding any additional strain to the US shipyards that are already under pressure and busy building complex warships that often take years to make.
Blue Water says it can design and build a prototype autonomous warship in just 18 months, making dozens a year at smaller but fully equipped shipyards across the US. The company has already discussed partnerships with several such facilities.
"Manned ships are complicated, exquisite, and extensive, and they cost billions of dollars," Gray said. "Unmanned ships are much simpler form factors. We can produce 50 per year in medium-sized yards."
Blue Water has a test vessel in the water at an undisclosed location in New England. The company said it is evaluating the hardware, software, and payloads for uncrewed ships, and it has three different designs in the works.
Survivability is a key consideration in design. The ongoing Houthi attacks against key Red Sea shipping lanes raise questions about how autonomous warships survive in a time of anti-ship missiles and maritime strike drones.
Gray said Blue Water wants to put weapons on its uncrewed ships because electronic warfare capabilities won't be enough to defend the vessel from enemy drone attacks — adversaries will learn and adapt. He said that a kinetic defensive system is necessary for future conflicts; it could be either guns or surface-to-air missiles.
Ukraine is already showing other militaries how weapons systems can be added to drone boats. Kyiv has armed uncrewed surface vessels with missile launchers, machine guns, and small drones and has used these platforms to wreak havoc on Russia's Black Sea Fleet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Miami Herald
3 hours ago
- Miami Herald
Whataburger debuts limited-time burger, plus a new treat. When can you get them?
Whataburger fans can soon sip — or sink their teeth into two new menu items. The Dr Pepper blackberry shake and bacon wrangler double arrive Tuesday, Aug. 5, at participating restaurants nationwide, according to the Texas-based burger chain. The limited-time offerings are the latest to land at Whataburger as the brand celebrates 75 years, marking 'its diamond anniversary' with new and returning menu favorites. In a nod to its Texas roots, the bacon wrangler double features two beef patties topped with bacon, American and Monterey Jack cheeses, crispy onions and garlic aioli on a toasted bun, Whataburger said in a news release. 'As a proud Texas-born brand, Whataburger was built on bold flavors, genuine hospitality and a spirit that feels like home,' President and CEO Debbie Stroud said in the release. 'The Bacon Wrangler Double is a delicious reminder that you can always experience a little bit of that spirit with every bite.' Customers can wash it all down with the new Dr Pepper blackberry shake, also available for a limited time. It's a fruity take on the original Dr Pepper shake, combining Whataburger's vanilla soft serve with Dr Pepper 'and a touch of blackberry flavor,' according to the restaurant's website. The burger chain offered a Dr Pepper blackberry-flavored soda at restaurants earlier this year to rave reviews. 'We paired two Texas favorites in a way that feels fresh but familiar — fun, unexpected, and full of that signature Whataburger deliciousness,' Scott Hudler, chief marketing officer for Whataburger, said at the time. Pricing information wasn't immediately available. Find your nearest Whataburger here.


Axios
3 hours ago
- Axios
U.S. "halfway there" with China on rare earth minerals, trade rep says
The U.S. is making progress in talks with China on access to rare earth minerals and other trade issues, but an extension to their tariff truce isn't yet final, U.S. Trade Representative Jamieson Greer said Sunday. Why it matters: The China trade relationship is of paramount importance to U.S. business leaders and financial markets, particularly the access to rare earth magnets, a crucial component for hundreds of products. That access was the core piece of the trade truce struck in Geneva in May, and the subsequent talks in London in June after the truce faltered. Both sides met again this past week in Stockholm to keep negotiating. What they're saying: " China has put a global control on the world, and so for the United States, we're focused on making sure that the flow of magnets from from China to the United States and the - and the adjacent supply chain can flow as freely as it did before the control, and I'd say we're about halfway there," Greer told"Face the Nation" host Margaret Brennan. The intrigue: The tariff-lowering truce between the world's two largest economies is due to expire on Aug. 12. After the Stockholm talks, the Chinese said it would be extended, but U.S. officials have said their counterparts got ahead of themselves. "That's something we're working toward. That's what we talked about," Greer said, adding that the final decision remained with President Trump.